+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Small Cell Lung Cancer (SCLC)- Epidemiology Forecast to 2030

  • ID: 5023867
  • Report
  • April 2020
  • Region: Global
  • 100 pages
  • DelveInsight
1 of 2

This report delivers an in-depth understanding of the disease, historical and forecasted Small Cell Lung Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Small Cell Lung Cancer (SCLC) Understanding

Small cell lung cancer (SCLC) is a fast-growing lung cancer. It usually starts in bronchi (center of the chest). Though the cancer cells are small, but they grow aggressively and create large tumors. This type of lung cancer represents about 15% of lung cancers and is typically caused by tobacco smoking. These kinds of tumors often metastasize quickly to other parts of the body. SCLC have two stages such as; limited-stage and extensive-stage. The primary goal of staging in SCLC is to determine whether the cancer has spread or not. Limited stage-SCLC, means that the cancer is only in one lung and maybe in lymph nodes on the same side of the chest.

“Additionally, in Extensive-Stage SCLC, tumors spreads beyond the supraclavicular areas, or with distant metastases. It has been observed that about three-quarters of SCLC patients are diagnosed with extensive-stage disease.”

According to the American Cancer Society, Extensive stage of SCLC is described as cancer that have spread widely throughout the lung, to the other lung, to lymph nodes on the other side of the chest, or to other parts of the body (including the bone marrow). Furthermore, many specialists consider SCLC, which has spread to the fluid around the lung to be extensive stage as well. In the case of extensive stage disease, which is more difficult to treat. Affected individuals are treated with chemotherapy and often radiation therapy. In a small group of people with very early stage cancer, surgery may be recommended. There are several risk factors that can lead to the development of SCLC. The primary risk factor of SCLC is tobacco use; almost all affected individuals smoke or have a history of smoking. In addition to this, the symptoms can vary from one person to another, and there are rarely any symptoms early in the course of the disease. The diagnosis of SCLC is based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized tests.

Epidemiology Perspective

The SCLC epidemiology division provides the insights about historical and current patient pool and forecasted trend for each seven major countries. The SCLC epidemiology data are studied through SCLC possible division to give a better understanding of the Disease scenario in 7MM. The SCLC epidemiology is segmented by epidemiology [segmented as Total Incident Patient Population, Gender-specific Incident Patient Population, Age-specific Incident Patient Population, Stage-Specific Incident Population, and Treatment of Extensive-Stage SCLC (first-line, second-line platinum sensitive, second-line platinum refractory, and third-line and above] covering the US, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Small Cell Lung Cancer Detailed Epidemiology Segmentation

  • Total incident population of SCLC in the 7MM was assessed to be 85,540 in 2017.
  • The estimates show highest Incident population of SCLC in the United States.
  • Among the European 5 countries, Germany had highest incident population of SCLC, followed by the United Kingdom and France. On the other hand, Spain had the lowest incident cases of SCLC.
  • SCLC has been observed across all ages and this makes age as one of the major factors for this condition. During the understanding of this indication and analyses of the various research paper, we have observed that SCLC cases are most common in middle-aged and older adults.
  • Patient progression from first to second line, i.e., platinum sensitive was approximately 20,745 in the 7MM. Patient progression from first to second line, i.e., Patient pool for Platinum refractory estimated to be around 17,351.

Scope of the Report

  • The SCLC report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The SCLC Report and Model provide an overview of the risk factors and global trends of SCLC in the seven major markets (7MM: US, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
  • The report provides insight about the historical and forecasted patient pool of SCLC in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of SCLC
  • The report provides the segmentation of the SCLC epidemiology by Age-specific Incident Cases of SCLC in 7MM
  • The report provides the segmentation of the SCLC epidemiology by Gender-specific Incident Cases of SCLC in 7MM
  • The report provides the segmentation of the SCLC epidemiology by Stage-Specific Incident Cases of SCLC in 7MM
  • The report provides the segmentation of the SCLC epidemiology by Line-wise Treatment of Extensive-Stage SCLC in 7MM

Report Highlights

  • 11-Year Forecast of Small Cell Lung Cancer epidemiology
  • 7MM Coverage
  • Total Incident Cases of Small Cell Lung Cancer
  • Incident Cases according to segmentation: Gender-specific, Age-specific, Stage-specific Incidence
  • Treated cases of Line-wise Treatment of Extensive-Stage Cases of Small Cell Lung Cancer

KOL-Views

The publisher interviews, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over SCLC scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Small Cell Lung Cancer
  • What are the key findings pertaining to the Small Cell Lung Cancer epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017-2030)?
  • What would be the total number of patients of Small Cell Lung Cancer across the 7MM during the study period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2017-2030)?
  • At what CAGR the patient population is expected to grow in the7MM during the study period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Small Cell Lung Cancer?
  • What are the current available treatments of Small Cell Lung Cancer? And how the prescription patters look like across the various line of therapies and how does it differ across the 7MM?
  • How many patients are responding to Platinum therapy after progression from first-line (% patients with Platinum Sensitive and Platinum Refractory)?
  • Between the limited and extensive SCLC, majority of patients are diagnosed with which conditions?

Reasons to Buy

The Small Cell Lung Cancer Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Small Cell Lung Cancer market
  • Quantify patient populations in the global Small Cell Lung Cancer market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Small Cell Lung Cancer therapeutics in each of the markets covered
  • Understand the magnitude of Small Cell Lung Cancer population by its severity
  • The Small Cell Lung Cancer epidemiology report and model were written and developed by Masters and PhD level epidemiologists
  • The Small Cell Lung Cancer Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030
Total incident cases of SCLC in the 7MM was assessed to be 85,540 in 2017, and are expected to increase during the study period. Among the European 5 countries, Germany had highest incident population of SCLC, followed by the United Kingdom and France. On the other hand, Spain had the lowest incident cases of SCLC in 2017. Furthermore, Japan accounts for the 21% of the 7MM patient population of SCLC. Furthermore, in 2017, a more number of males were affected by the disease, i.e., 55% of the SCLC cases in the 7MM, in comparison to the females. However, the incidence gap between males and females has narrowed over the past three decades.

Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Executive Summary of SCLC

3. SWOT Analysis for SCLC

4. SCLC: Market Overview at a Glance
4.1. Total Market Share (%) Distribution of SCLC in 2017
4.2. Total Market Share (%) Distribution of SCLC in 2030

5. Small Cell Lung Cancer (SCLC): Disease Background and Overview
5.1. Introduction
5.1.1. Signs and Symptoms of Lung Cancer
5.1.2. Risk Factors of SCLC
5.1.3. Causes of SCLC
5.1.4. Disease Biology: SCLC
5.2. Diagnosis of Small-cell Lung Cancer (SCLC)
5.2.1. Imaging tests
5.2.2. Staging in SCLC

6. Epidemiology and Patient Population
6.1. Epidemiology Key Findings
6.2. Assumptions and Rationale: 7MM
6.3. Total Incidence of Lung Cancer in the 7MM
6.4. Total Incidence cases of SCLC in the 7MM

7. United States
7.1. Total Incidence cases of SCLC in the United States
7.2. Gender-specific Incidence of SCLC in the United States
7.3. Age-specific Incidence of SCLC in the United States
7.4. Stage-Specific Incidence of SCLC in the United States
7.5. Line-wise Treatment of Extensive-Stage SCLC in the United States

8. EU-5 Country-wise Epidemiology
8.1. Germany
8.1.1. Total Incidence cases of SCLC in Germany
8.1.2. Gender-specific Incidence of SCLC in Germany
8.1.3. Age-specific Incidence of SCLC in Germany
8.1.4. Stage-Specific Incidence of SCLC in Germany
8.1.5. Line-wise Treatment of Extensive-Stage SCLC in Germany
8.2. France
8.2.1. Total Incidence cases of SCLC in France
8.2.2. Gender-specific Incidence of SCLC in France
8.2.3. Age-specific Incidence of SCLC in France
8.2.4. Stage-Specific Incidence of SCLC in France
8.2.5. Line-wise Treatment of Extensive-Stage SCLC in France
8.3. Italy
8.3.1. Total Incidence cases of SCLC in Italy
8.3.2. Gender-specific Incidence of SCLC in Italy
8.3.3. Age-specific Incidence of SCLC in Italy
8.3.4. Stage-Specific Incidence of SCLC in Italy
8.3.5. Line-wise Treatment of Extensive-Stage SCLC in Italy
8.4. Spain
8.4.1. Total Incidence cases of SCLC in Spain
8.4.2. Gender-specific Incidence of SCLC in Spain
8.4.3. Age-specific Incidence of SCLC in Spain
8.4.4. Stage-Specific Incidence of SCLC in Spain
8.4.5. Line-wise Treatment of Extensive-Stage SCLC in Spain
8.5. United Kingdom
8.5.1. Total Incidence cases of SCLC in the United Kingdom
8.5.2. Gender-specific Incidence of SCLC in the United Kingdom
8.5.3. Age-specific Incidence of SCLC in the United Kingdom
8.5.4. Stage-Specific Incidence of SCLC in the United Kingdom
8.5.5. Line-wise Treatment of Extensive-Stage SCLC in the United Kingdom

9. Japan
9.1. Total Incidence cases of SCLC in Japan
9.2. Gender-specific Incidence of SCLC in Japan
9.3. Age-specific Incidence of SCLC in Japan
9.4. Stage-Specific Incidence of SCLC in Japan
9.5. Line-wise Treatment of Extensive-Stage SCLC in Japan

10. Appendix
10.1. Bibliography
10.2. Report Methodology

11. Disclaimer

12. The Publisher's Capabilities

13. About the Publisher
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll